Anti-Tumor Autoimmunity by lymphopenia T cell Expansion

通过淋巴细胞减少 T 细胞扩增来抗肿瘤自身免疫

• 批准号: 7369853
• 负责人: ROBERTO G BACCALA
• 金额: $ 32.89万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7369853
• 关键词: Address; Antigen Presentation; Antigen-Presenting Cells; Antigens; Area; Autoantigens; Autoimmune Process; Autoimmunity; Cell Count; Chimera organism; Condition; Cross Presentation; Dendritic Cells; Disease; Epitopes; Frequencies; Haplotypes; Immune Response Genes; Immunotherapy; Investigation; Kinetics; Ligands; Lymphocyte; Lymphopenia; Maintenance; Melanoma Cell; Modeling; Molecular; Monoclonal Antibodies; Mus; Nature; Numbers; Pathway interactions; Peptide/MHC Complex; Peptides; Peripheral; Phase; Process; Proliferating; Proteins; Recombinant Cytokines; Relative (related person); Research Personnel; Role; Staging; T memory cell; T-Cell Proliferation; T-Lymphocyte; Testing; Therapeutic; Transgenic Organisms; Tumor Antigens; base; cancer cell; cancer immunotherapy; cancer therapy; clinical application; cytokine; cytotoxicity; improved; in vivo; melanoma; neoplastic cell; novel; novel strategies; programs; research study; response; size; tumor

DESCRIPTION (provided by applicant): Since tumor-associated antigens are primarily encoded by normal unmutated genes, the immune responses elicited by an effective cancer immunotherapy are essentially autoimmune in nature. However, breaking tolerance for self-antigens remains a major challenge. Recent studies showed that, under lymphopenic conditions, peripheral T cells proliferate to re-establish appropriate cell numbers. Such homeostatic T cell proliferation depends on recognition of self-peptide/MHC ligands and is accompanied by acquisition of several activation markers and effector functions, including cytotoxicity. On this basis, we hypothesized that induction of homeostatic T cell proliferation concurrent with tumor cell challenge may be a way to preferentially expand and activate otherwise tolerant lymphocytes and, hence, elicit effective anti-tumor autoimmunity. Our preliminary experiments with melanoma cell-challenged lymphopenic mice transferred with small numbers of syngeneic T cells indicated that this is indeed the case. Here, we wish to extend this novel observation by examining the clinical applicability, particularly the mechanistic basis of this approach. Specific Aims include (a) defining the efficacy of homeostatic T cell proliferation on established tumors at different disease stages; (b) exploring the role of direct presentation by tumor cells versus cross-presentation by antigen-presenting cells during T cell homeostatic expansion and priming; (c) evaluating mechanisms of T cell selection and break of tolerance for tumor antigens; and (d) determining whether the anti-tumor effect can be improved by supplementing trophic cytokines that promote homeostatic T cell proliferation and survival, and enhance maintenance of memory T cells. The results will define the role of homeostatic T cell proliferation in tumor autoimmunity, and provide new approaches to the treatment of cancer.

描述（由申请人提供）：由于肿瘤相关抗原主要由正常未突变基因编码，因此有效的癌症免疫疗法引发的免疫反应本质上是自身免疫的。然而，打破对自身抗原的耐受性仍然是一个重大挑战。最近的研究表明，在淋巴细胞减少的情况下，外周 T 细胞会增殖以重新建立适当的细胞数量。这种稳态 T 细胞增殖依赖于自身肽/MHC 配体的识别，并伴随着多种激活标记和效应功能的获得，包括细胞毒性。在此基础上，我们假设在肿瘤细胞攻击的同时诱导稳态T细胞增殖可能是一种优先扩增和激活其他耐受淋巴细胞的方法，从而引发有效的抗肿瘤自身免疫。我们对转移了少量同基因 T 细胞的黑色素瘤细胞攻击的淋巴细胞减少小鼠进行的初步实验表明情况确实如此。在这里，我们希望通过检查临床适用性，特别是这种方法的机制基础来扩展这一新颖的观察结果。具体目标包括 (a) 确定稳态 T 细胞增殖对不同疾病阶段已形成肿瘤的功效； (b) 探索在 T 细胞稳态扩增和启动过程中肿瘤细胞直接呈递与抗原呈递细胞交叉呈递的作用； (c) 评估T细胞选择和破坏肿瘤抗原耐受性的机制； (d)确定是否可以通过补充促进稳态T细胞增殖和存活并增强记忆T细胞维持的营养细胞因子来提高抗肿瘤效果。研究结果将明确稳态 T 细胞增殖在肿瘤自身免疫中的作用，并为癌症治疗提供新方法。